# Study Of Cognitive ReAlignment Therapy in Early Schizophrenia

Submission date	Recruitment status	Prospectively registered
23/10/2000	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
23/10/2000	Completed	[X] Results
Last Edited	Condition category	Individual participant data
23/09/2009	Mental and Behavioural Disorders	

## Plain English summary of protocol

Not provided at time of registration

# Contact information

## Type(s)

Scientific

#### Contact name

**Professor SW Lewis** 

#### Contact details

School of Psychiatry and Behavioural Science University of Manchester Withington Hospital West Didsbury Manchester United Kingdom M20 8LR

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

G9519373

# Study information

#### Scientific Title

#### **Acronym**

**SOCRATES** 

#### Study objectives

To evaluate the effectiveness of cognitive behaviour therapy in parallel with drug treatments as usual in early acute schizophrenia. The hypothesis is that CBT is an acceptable adjunct to drug treatment which will accelerate resolution of target psychotic symptoms and reduce relapse.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

## Primary study design

Interventional

# Secondary study design

Randomised controlled trial

#### Study setting(s)

Not specified

#### Study type(s)

**Not Specified** 

#### Participant information sheet

## Health condition(s) or problem(s) studied

Neurosciences, psychiatry

#### **Interventions**

Cognitive behaviour therapy/drug treatments

#### Intervention Type

Other

#### **Phase**

**Not Specified** 

## Primary outcome measure

- 1. Change on core symptom scores on hallucination and delusion rating scales
- 2. Change in total symptoms scores on PANSS
- 3. Time to criterion of 50% recovery operationally defined -
- 4. Number of days in hospital before 1st discharge and during follow-up
- 5. Time to relapse
- 6. Follow-up symptom and outcome scores at 3.9 and 18 months

#### Secondary outcome measures

Not provided at time of registration

## Overall study start date

01/04/1996

#### Completion date

31/03/2000

# **Eligibility**

#### Key inclusion criteria

Consecutive sample of in- or day-patients admitted with 1st and 2nd episode schizophrenia aged 18-65. Further inclusion criteria:

- 1. Able to give informed consent
- 2. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSMIV) diagnostic criteria for schizophrenia, schizophreniform or schizoaffective disorder with at least a 1 month history of positive symptoms
- 3. No significant history of organic brain disease or substance misuses for major aetiological factor for psychosis
- 4. Positive and negative syndrome scale (PANSS) for schizophrenia score of at least 4 on item hallucinatory behaviour and/or item delusions
- 5. Score of less than 5 on PANSS item conceptual disorganisation

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Lower age limit

18 Years

#### Upper age limit

65 Years

#### Sex

**Not Specified** 

#### Target number of participants

236

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/04/1996

#### Date of final enrolment

31/03/2000

# Locations

#### Countries of recruitment

England

United Kingdom

# Study participating centre School of Psychiatry and Behavioural Science

Manchester United Kingdom M20 8LR

# Sponsor information

## Organisation

Medical Research Council (MRC) (UK)

#### Sponsor details

20 Park Crescent London United Kingdom W1B 1AL +44 (0)20 7636 5422 clinical.trial@headoffice.mrc.ac.uk

#### Sponsor type

Research council

#### Website

http://www.mrc.ac.uk

# Funder(s)

# Funder type

Research council

#### Funder Name

Medical Research Council (MRC) (UK)

# Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

#### **Funding Body Type**

Government organisation

# **Funding Body Subtype**

National government

#### Location

**United Kingdom** 

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

# Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2002		Yes	No